NCT00523640

A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out what effects (good and bad) the combination of the chemotherapy drugs gemcitabine, capecitabine, and bevacizumab has on a patient and kidney cancer.

Detailed description

* to determine the objective response rate and estimate the time to progression of combination gemcitabine, capecitabine, and bevacizumab in patients with metastatic clear cell renal cell cancer; * to determine survival of combination gemcitabine, capecitabine, and bevacizumab in patients with metastatic cell renal cell cancer; * to determine the toxicity of combination gemcitabine, capecitabine, and bevacizumab in patients with metastatic renal cell cancer; * to collect baseline serum and plasma samples for exploration of possible prognostic and predictive markers

Conditions

• Carcinoma, Renal Cell

Interventions

Type	Name	Description
DRUG	combination of gemcitabine, capecitabine, and bevacizumab	gemcitabine 1000 mg/m\^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle

Timeline

• Start date: 2005-03-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2007-08-31
• Last updated: 2014-02-11
• Results posted: 2011-12-22

Locations

1 site across 1 country: United States